Vitamin D therapy in patients receiving dialysis

Area of Science:

• Nephrology
• Endocrinology
• Mineral and Bone Disorders

Background:

• Secondary hyperparathyroidism is prevalent in dialysis patients.
• Calcitriol controls moderate hyperparathyroidism but is less effective in advanced stages, particularly with nodular parathyroid hyperplasia.
• Nodular hyperplasia may involve monoclonal growth and reduced calcitriol receptor expression, impacting treatment response.

Purpose of the Study:

• To review the efficacy and administration of calcitriol in managing secondary hyperparathyroidism in dialysis patients.
• To discuss alternative treatments like parathyroidectomy for specific patient groups.
• To highlight considerations for calcitriol therapy, including dosage, administration routes, and monitoring.

Main Methods:

• Review of existing literature on calcitriol treatment for secondary hyperparathyroidism.
• Analysis of factors influencing calcitriol response, such as disease stage and parathyroid gland morphology.
• Discussion of different calcitriol administration strategies (oral vs. intravenous, continuous vs. intermittent).

Main Results:

• Calcitriol is effective for moderate hyperparathyroidism; response is variable in advanced disease and nodular hyperplasia.
• Parathyroidectomy is a viable alternative for patients with nodular parathyroid hyperplasia.
• Intermittent calcitriol administration may be superior to continuous, though clinical evidence is limited.
• Close monitoring is essential to prevent hypercalcemia, hyperphosphatemia, and adynamic bone disease.

Conclusions:

• Calcitriol is a key treatment for secondary hyperparathyroidism in dialysis patients, but its efficacy varies.
• Parathyroidectomy should be considered for patients with nodular hyperplasia unresponsive to calcitriol.
• Careful management of calcitriol therapy is crucial to optimize outcomes and avoid complications like adynamic bone disease.